Pneumococcal disease remains a leading cause of morbidity and mortality among adults, yet gaps in protection persist. This session will review the evolving epidemiology and discuss the limitations of previous vaccines. Recent evidence supporting Prevenar 20 (PCV20) will be presented, demonstrating its broader serotype coverage and enhanced clinical benefits for comprehensive adult protection.